Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

January 1, 2026

Conditions

Carcinoma, Renal CellFumarate Hydratase DeficiencyImmunotherapy

Interventions

DRUG

Sintilimab injection plus Inlyta treatment

Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC

Trial Locations (1)

West China Hospital, Chengdu

All Listed Sponsors

lead

West China Hospital

OTHER